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ABSTRACT
Androgen deprivation therapy (ADT) is the
mainstay palliative treatment for men with
locally advanced and metastatic prostate
cancer, and aims to reduce testosterone to
levels obtained by surgical castration. Use of
gonadotropin-releasing hormone (GnRH)
agonists predominates among the ADT
options. The GnRH agonist, triptorelin is a
first-line hormonal therapy that has
demonstrated efficacy and safety in clinical
trials of patients with locally advanced
non-metastatic or metastatic disease.
Sustained-release 1-, 3- and 6-month
formulations of triptorelin, administered
intramuscularly or subcutaneously, have been
developed to provide improved flexibility and
convenience for the patient. Head-to-head
studies of GnRH agonists are lacking in the
field of prostate cancer. Despite the
inevitable progression to castration-resistant
prostate cancer (CRPC) in most patients
receiving ADT, monitoring of testosterone
levels needs to improve in routine practice and
physicians should not overlook the benefits of
continued ADT in their patients when
introducing one of the various new treatment
options for CRPC. For improved survival
outcomes, there remains a need to tailor ADT
treatment regimens, novel hormonal agents
and chemotherapy according to the individual
patient with advanced prostate cancer.
Keywords: Androgen deprivation therapy;
Oncology; Prostate cancer; Sustained-release
formulations; Triptorelin
INTRODUCTION
Prostate cancer is the most frequently occurring
cancer among European men, with an
estimated incidence of 416,700 (varying from
25 to 193 per 100,000 populations in different
European countries) and an estimated 92,200
deaths in 2012 [1]. In the USA, incidence of
prostate cancer is within this European range at
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138 per 100,000 populations according to the
Surveillance, Epidemiology, and End Result
program [2]. Hereditary factors are important
for determining the risk of developing prostate
cancer and exogenous factors may have an
impact on the risk of progression. However, in
general, the risk factors for prostate cancer are
poorly understood and consequent advice on
prevention is not possible [3]. Therefore, the
management of prostate cancer focuses on
treating the disease, and the hormone
dependence of prostate cancer has been
recognized for decades [4]. As a consequence,
testosterone suppression has been the standard
palliative treatment in men with advanced
prostate cancer for many years. Orchiectomy is
a simple, low-cost surgical procedure that
effectively and quickly achieves castration, but
because it is irreversible and does not allow
intermittent treatment, it has become less
popular than hormonal therapies among
patients.
The selection of appropriate treatment is
mainly dependent on the stage of disease and
the risk of progression. Prostate cancer is
generally described as localized, locally
advanced (when the tumor has extended
beyond the capsule of the prostate) and
metastatic disease, and is classified using the
Tumor-lymph Nodes-Metastasis (TNM) system
[5]. Patients are also categorized into low, high,
or intermediate risk of progression according to
clinical stage, Gleason score, and
prostate-specific antigen (PSA) level [6], and
this will continue with the adoption of the
recent International Society of Urological
Pathology (ISUP) modified Gleason grading
patterns [7]. However, a recent assessment of a
large cohort found that while high levels of PSA
([100 ng/ml) at diagnosis were associated with
a reduction in survival after 5 and 10 years,
within this high-risk group PSA level was not
associated with prostate cancer-specific
mortality [8]. Gleason score and the presence
of metastasis were the strongest predictors of
prostate cancer-specific mortality in this group
with high PSA at presentation [8]. What is clear
is that patients classified as having low or
intermediate risk prostate cancer (Gleason
score \8 and PSA \20 ng/ml) may have a
10-year prostate cancer-specific mortality of
\5% [9, 10], and avoiding unnecessary
treatment is a challenge in these patients
[11, 12]. Patients with high-risk prostate
cancer make up a considerable proportion of
newly diagnosed patients and have much
higher mortality rates, and therefore, the
challenge in these men is to increase overall
survival while reducing any adverse effects of
treatment. However, this high-risk population
is heterogeneous and more information is
needed on the validity of suggested prognostic
indicators, such as the number and location of
bone metastases, visceral metastases, Gleason
score, and the initial PSA level [3, 13].
This article reviews the current and ongoing
role of androgen deprivation therapy (ADT) in
the management of prostate cancer, with a
particular focus on clinical trial and real-world
evidence supporting the use of the
gonadotropin-releasing hormone (GnRH)
agonist triptorelin in men with locally
advanced or metastatic prostate cancer. As
such, this article is based on previously
conducted studies, and does not involve any
new studies of human or animal subjects
performed by any of the authors.
THE ROLE OF ADT IN PROSTATE
CANCER MANAGEMENT
ADT aims to reduce testosterone levels to the
levels achieved with surgical castration [defined
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as \50 ng/dl (\1.7 nmol/l) by regulatory
authorities and used in clinical trials, but
\20 ng/dl may be a more clinically
meaningful definition of castration] [3].
ADT is recommended for patients with
locally advanced prostate cancer and
metastatic prostate cancer [3]. In the case of
locally advanced prostate cancer, ADT is
recommended only when patients are
unwilling or unable to receive any form of
local treatment and who are symptomatic or
asymptomatic with a PSA doubling time
(PSA-DT) \12 months and a poorly
differentiated tumor. ADT is also
recommended for lymph node positive (N1)
prostate cancer whether newly diagnosed or
after extended lymph node dissection. In both
situations, additional radiation therapy may
have a role. ADT using GnRH agonists should
be combined at treatment initiation with the
short-term administration of anti-androgens to
prevent flare-up of symptoms due to the initial
pituitary stimulation and increase in
testosterone levels [3].
Androgen deprivation can be achieved with
a number of different types of ADT, including
GnRH agonists, GnRH antagonists, and
oestrogens. Anti-androgens are also sometimes
used to inhibit the action of androgens. GnRH
agonists, of which the most widely used include
triptorelin, goserelin, and leuprolide, stimulate
gonadotropins from the anterior pituitary gland
and the production of testosterone in men, but
continued administration leads to the
downregulation of pituitary GnRH receptors,
which quickly results in the suppression of
gonadotropins [luteinising hormone (LH) and
follicle stimulating hormone (FSH)] followed by
a decrease in testosterone levels [14, 15]. GnRH
antagonists (e.g., degarelix) competitively bind
to the pituitary GnRH receptors and directly
inhibit the release of gonadotropins and lead to
reduced testosterone levels [16]. Oestrogens
induce pituitary suppression of gonadotropin
secretion and inhibit the production of
androgens in the testicles but are rarely used
due to their side effect profile [17].
Anti-androgens, which bind to androgen
receptors and thereby block the effect of
endogenous androgens, are used in
combination with GnRH agonists to achieve
complete androgen blockade (CAB) [18]. In the
short term, the concomitant use of
anti-androgens prevents the flare-up that can
occur when initiating GnRH agonist therapy
[18]. Anti-androgens include bicalutamide,
flutamide, and the more recently developed
enzalutamide [19]. Moreover, abiraterone is a
novel androgen synthesis inhibitor that has
been shown to block androgen synthesis in
adrenal glands and prostate cancer cells. Both
abiraterone and enzalutamide are generally
indicated for second-line treatment when
castration resistance develops with ADT
[20–22].
While ADT is effective for reducing
testosterone and PSA levels, almost all men
treated in the long term develop
castrate-resistant prostate cancer (CRPC)
[23, 24], with more than 80% exhibiting bone
metastases upon diagnosis of CRPC.
TRIPTORELIN AS ADT
The most widely used ADT in clinical practice is
GnRH agonist therapy, and one frequently
prescribed agent is triptorelin (Decapeptyl,
Pamorelin, Diphereline, Arvekap, Ipsen,
Paris, France). In line with European
Association of Urology (EAU) guidelines [3],
triptorelin is indicated as the first-line
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hormonal therapy in patients with locally
advanced non-metastatic or metastatic disease
as an alternative to surgical castration; and as
add-on to external-beam radiation therapy.
Triptorelin is administered to patients in the
form of acetate or pamoate (also known as
embonate) salts, and in response to the need for
ADT regimens that improve convenience and
treatment adherence, sustained-release
1-month (3 or 3.75 mg), 3-month (11.25 mg),
and 6-month (22.5 mg) formulations of
triptorelin have been developed (Fig. 1)
[25–27]. Sustained-release formulations of
triptorelin comprise microparticles of the
decapeptide incorporated within a
biocompatible and biodegradable copolymer
(polylactide-co-glycolide) [28].
Pharmacokinetics
Following intravenous bolus administration,
triptorelin is distributed and eliminated by
hepatic and renal routes according to a
three-compartment model that corresponds to
plasma half-lives of 6 min, 45 min, and 3 h [27].
Sustained-release intramuscular (IM)
administration of triptorelin initially
stimulates LH and FSH secretion, with the
subsequent production of testosterone [27].
Bioequivalence studies suggest a maximal
increase in testosterone at around 4 days
post-triptorelin administration. Testosterone
levels progressively decline after this initial
increase with continuous exposure to
triptorelin [27]. Romero et al. developed a
Fig. 1 Structure of triptorelin acetate (a) and pamoate (b) [82, 83]
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pharmacokinetic/pharmacodynamics model
indicating that 95% of patients with
steady-state concentrations of triptorelin
(Cmin) higher than 0.0609 ng/ml were kept
castrated [29].
Triptorelin is usually administered by IM
injection. After the first month, mean serum
levels of triptorelin are stable at 0.06 ng/ml for
approximately 12 weeks after a single IM
injection of a triptorelin pamoate 3-month
formulation, with mean (standard deviation)
Cmax of 35.7 ng/ml (18.3 ng/ml) and Cmin of
0.063 ng/ml (range 0.021–0.174 ng/ml) [30]. A
single IM administration of the 6-month
formulation of triptorelin pamoate produced a
Cmax of 40.0 ng/ml (range 22.2–76.8 ng/ml)
[15].
Patients are also offered greater flexibility by
the availability of subcutaneous (SC) injections
of triptorelin [31]. The IM route of
administration may not be suitable for all
patients (for example, the risk of excessive
bleeding or haematomas in those receiving
anticoagulants) [32], and so SC injections
provide an alternative delivery option. The key
pharmacokinetic parameters (such as Cmax and
Cmin) with the SC injection of a triptorelin
pamoate 11.25 mg 3-month formulation are in
the same range as observed for the IM injection
[30, 31].
Clinical Efficacy
A significant body of evidence supports the
efficacy and safety of sustained-release
formulations of triptorelin for the treatment of
patients with locally advanced non-metastatic
or metastatic prostate cancer (Table 1).
The biochemical effectiveness of ADT is
measured by determining if testosterone levels
are reduced by treatment to castrate levels
(serum testosterone\50 ng/dl or\1.7 nmol/l).
In addition, more stringent definitions of
castration have been proposed, such as serum
testosterone\20 ng/dl [33]. Other cut-offs, such
as 30 or 32 ng/dl, have also been proposed
[34–36]. PSA levels are also utilized as a measure
of treatment response. However, PSA
measurement has many limitations; for
example, there is little precision on the
predictive value of PSA levels, there is no
consensus on the magnitude or duration of
PSA decline that can be used to define response,
and PSA kinetics have little value in guiding
management decisions. Nevertheless, in the
absence of better surrogate markers, PSA
decline is used as a secondary efficacy criterion
in clinical trials of ADT. Ultimately, a decrease
in testosterone level remains the primary
biochemical surrogate efficacy parameter of
medical castration.
Following promising data from early trials of
depot formulations of triptorelin [37], the
ability of the triptorelin 3.75 mg 1-month and
the triptorelin 11.25 mg 3-month formulations
to achieve castration 3–4 weeks after
administration and to maintain it between the
injections was demonstrated in key clinical
trials encompassing 14–140 men with
advanced prostate cancer [30, 38–41]. In the
largest of these studies, castrate levels of
testosterone were reached after 28 days in
91.2% of 140 men randomized to treatment
with the triptorelin 3.75 mg 1-month
formulation [40]. Moreover, in an open-label,
non-comparative, Phase III study of 120 men
with locally advanced or metastatic prostate
cancer, the triptorelin 22.5 mg 6-month
formulation was shown to achieve castrate
levels of testosterone in 97.5% of patients after
28 days and in 98.3% after 12 months [15].
Similarly, [90% of patients achieved castrate
levels of testosterone 1, 3, and 6 months after
injection of triptorelin 22.5 mg in the recent
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Triptocare study in 326 adult men with locally
advanced or metastatic prostate cancer who
were naı¨ve to ADT [42] (Fig. 2). Castration is
also maintained in the longer term [43]. The
Triptocare LT study (ClinicalTrials.gov
identifier, NCT01383863) showed that castrate
levels of testosterone were maintained 3 years
after starting ADT in men recruited into the
Triptocare study; however, regular
measurement of testosterone levels was
infrequent in routine clinical practice [44].
In general, similar results have been reported
internationally in ethnically different
populations [15, 45, 46].
In addition to the standard castrate
testosterone threshold of\50 ng/dl, the 1-, 3-,
and 6-month formulations of triptorelin have
been shown to achieve the most stringent
definition of castration (i.e., serum
testosterone\20 ng/dl) in[90% of patients at
6, 9, and 12 months post-IM injection [28, 47].
Although this more stringent definition of
castration has not been widely adopted, the
EAU guidelines state that a \20 ng/dl cut-off
would be more appropriate, as better results are
observed with lower levels of testosterone
compared to 50 ng/dl [3]. It is, therefore,
important to demonstrate in clinical trials
that a high proportion of patients achieves
this lower level with ADT.
The sustained suppression of testosterone
with these triptorelin formulations leads to
reductions in PSA levels. The triptorelin
3.75 mg 1-month formulation was shown to
reduce median PSA levels from 46.8 ng/ml at
baseline to 1.3 ng/ml at 9 months in 140 men
with advanced prostate cancer [40]. Likewise,
triptorelin 11.25 mg 3-month formulations
reduced serum PSA level in treated patients
[39, 45]. In one of these studies, 41 patients
with newly diagnosed locally advanced or
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triptorelin 11.25 mg 3-month formulation and
showed reductions in median PSA from
112.7 ng/ml at baseline to 10.4 and 11.6 ng/ml
at 3 and 6 months, respectively [45]. Substantial
PSA decreases were also observed with the
triptorelin 22.5 mg 6-month formulation from
84 days post-injection [15, 42] (Fig. 2). The
longer term Triptocare LT study, which
included 180 patients who had participated in
and received triptorelin treatment in the
Triptocare study, showed that median serum
PSA reductions were maintained after 3 years of
ADT [44]. The median time to PSA nadir was
185 days [44].
All of the aforementioned efficacy data were
reported with the IM administration of
triptorelin. Recently, SC administration of
triptorelin pamoate 11.25 mg 3-month
formulation was shown to achieve castrate
levels of testosterone within 4 weeks of the
Fig. 2 Change in testosterone (a) and serum PSA (b) levels from baseline with sustained-release 22.5 mg 6-month
triptorelin in men with advanced prostate cancer [42]. PSA prostate-speciﬁc antigen
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first injection in 97.6% of men with locally
advanced or metastatic prostate cancer [31].
Treated patients reached testosterone levels of
\50 ng/dl after a median of 22 days and
maintained castration until study end at
26 weeks (in 96.6% of those who achieved
castration at 4 weeks) [31]. Most patients
(77.7%) also met the stringent castration
definition of testosterone concentration
\20 ng/dl at 4 weeks, increasing to 90.8%
after 26 weeks. In this study, PSA levels were
also reduced from baseline by 64.2% and
96.0% at 4 and 26 weeks after injection, with
median PSA levels below 4 ng/ml from week 8
through week 26 [31]. These data suggest that
the route of triptorelin administration can be
switched from IM to SC without compromising
efficacy.
Effect on Symptoms
Up to 40% of men with localized prostate
cancer may have moderate or severe lower
urinary tract symptoms (LUTS) [48], but data
on the impact of ADT on LUTS are limited
[49–51]. Recently, the preliminary results of an
observational study in six countries suggested
that treatment with triptorelin 1- and 3-month
formulations improved LUTS after 6 and
12 months, as measured by a significant
reduction in the International Prostate
Symptom Score (IPSS) [52]. Interestingly, the
improvement in LUTS after triptorelin therapy,
correlated with reductions in PSA levels [52].
Similar results were observed in a prospective
observational study that included 325 Belgian
patients with locally advanced or metastatic
prostate cancer, the majority of whom (62%)
had moderate (IPSS 8-19) to severe (IPSS C 20)
LUTS at study entry [53]. After 24 and 48 weeks
of treatment with triptorelin 3.75 mg and/or
11.25 mg formulations, mild or no LUTS were
reported in 25.7% and 33.5% of patients,
respectively [53].
The triptorelin 1- and 3-month formulations
have also been associated with improvement in
other clinical symptoms, including bone pain
[40, 41, 45], but further study on bone pain
relief is needed.
Tolerability
Across clinical trials of patients with advanced
prostate cancer, sustained-release triptorelin 1-,
3- and 6-month formulations were generally
well tolerated, and the safety profile is
consistent between the sustained-release
formulations [15, 28, 31, 40, 42, 54]. The most
frequently occurring treatment-related adverse
events (AEs) with both IM and SC
administrations of triptorelin were
characteristic of those observed following any
GnRH agonist treatment and are due to the
expected pharmacological effect of the drug,
i.e., castration [15, 31]. Such AEs with IM
administration included hot flushes (50% of
patients), erectile dysfunction (4%), and
decreased libido (3%) [26, 27]. Similarly, hot
flushes (10.3%) were the most frequently
reported AE with the SC administration of
triptorelin followed by increased weight (5.6%)
[31].
Despite these AEs, discontinuation rates
while receiving triptorelin are infrequent. For
example, the IM administered triptorelin
22.5 mg 6-month formulation led to no
withdrawals due to AEs in the pivotal trial of
this formulation [15]. Equally, triptorelin
11.25 mg 3-month treatment did not lead to
discontinuations due to AEs when administered
by SC injection to patients with locally
advanced or metastatic prostate cancer [31].
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Triptorelin in Routine Clinical Practice
Reports of triptorelin efficacy in clinical trials
translate to real-world studies. For example, in
a grouped analysis of 1241 men from six
countries, mean PSA levels were 117.9 ng/ml
before the men initiated triptorelin therapy
and this was reduced to 8.5 and 16.6 ng/ml
after 6 and 12 months treatment, respectively
[52]. A recent preliminary report from the UK
indicated that PSA remained suppressed when
patients switched from any 3-month
formulation of GnRH agonist to the
triptorelin 22.5 mg 6-month formulation, and
this switch may help reduce hospital resource
use [55].
Studies of sustained-release formulations of
triptorelin during routine clinical practice also
demonstrate improvements in some aspects of
health-related quality of life (HRQoL) and
satisfaction in patients [52, 53, 55–58]. In an
observational study of everyday practice in
France, 1438 patients initiating treatment with
triptorelin 3- or 6-month formulations for
prostate cancer were evaluated for reasons for
prescription and patient preference. Most
patients initiated the 6-month formulation
(62.8% vs 37.2% for the 3-month
formulation), primarily for physician-reported
reasons relating to the simplification of the
treatment regimen and fewer unnecessary visits.
Most patients (*80%) were satisfied with their
prescribed formulation [57]. A second French
longitudinal, prospective study of elderly men
aged 75 years or older with prostate cancer
observed that 3–6 months of triptorelin
treatment did not adversely influence HRQoL.
Notably, triptorelin treatment improved
HRQoL related to urinary symptoms and
incontinence [56].
One notable observation in many studies in
routine practice is the low frequency of
testosterone measurement—for example, in
the Triptocare LT study, less than 20% of
patients had testosterone levels measured at all
time points [44]. Since testosterone level
remains the primary biochemical surrogate
efficacy parameter of medical castration in
prostate cancer, the low frequency of
testosterone measurement in practice is a
concern. Greater efforts should be made to
ensure testosterone measurement in future
observational studies and registries to improve
the quality of outcomes data, and initiatives,
such as the Prostate Cancer Outcomes
Registry-Australia and New Zealand, may help
in this respect [59].
ARE ALL ADTS THE SAME?
Several head-to-head trials have been
conducted of sustained-release 1-month
triptorelin acetate or pamoate versus
leuprolide acetate [39–41]. In the most recent
study, 284 men with advanced prostate cancer
were randomly assigned to receive triptorelin
pamoate 3.75 mg or leuprolide 7.5 mg every
28 days for 9 months (252 days). Triptorelin
and leuprolide demonstrated clinical
equivalence in the proportion of men
maintaining castrate serum testosterone
levels, defined as B50 ng/dl, between 2 and
9 months after starting treatment (mean levels
maintained below castration limit in 98.8% vs
97.3% of the patients; cumulative
maintenance castration rates of 96.2% vs
91.2%, respectively). Changes in the
secondary endpoints of LH levels, bone pain,
PSA levels, and quality of life were also not
significantly different between treatment
1086 Adv Ther (2016) 33:1072–1093
groups. However, triptorelin was associated
with a significantly higher 9-month survival
rate than leuprolide (97.0% vs 90.5%;
P = 0.033) [40].
However, in general, there is a lack of
head-to-head evaluations of GnRH agonists in
advanced prostate cancer, and the
aforementioned studies all used a 1-month
formulation of triptorelin. In the absence of
head-to-head data, cross-study comparisons
suggest similar efficacy of the sustained-release
6-month formulations of the GnRH agonists
triptorelin pamoate and leuprolide acetate, with
medical castration rates (serum testosterone
B50 ng/dl) of 97.5% and 97.0% at 29 days and
98.3% and 99.0% at 12 months, respectively
[60].
A technology appraisal commissioned by
the National Institute for Health Care and
Excellence (NICE) in the UK reviewed the
evidence supporting the use of the GnRH
antagonist degarelix for the treatment of
advanced prostate cancer and selected
leuprolide, goserelin, and triptorelin as
comparators [61]. A mixed treatment
comparison meta-analysis of a total of six
studies of the selected agents revealed that
leuprolide and goserelin were associated with
increased mortality compared with degarelix
(odds ratio [OR] 1.8 and 1.9, respectively). In
contrast, mortality with triptorelin was lower
than with degarelix (OR 0.5), leading the NICE
Evidence Review Group to consider that the
treatment effect of triptorelin on overall
survival may differ from that of leuprolide
and goserelin [61]. While this analysis is
intriguing, more large-scale head-to-head
comparisons would be needed to draw firm
conclusions on the effects of different ADTs on
survival.
THE ONGOING PLACE OF ADT
IN PROSTATE CANCER
MANAGEMENT
Two important topics on the role of ADT in
prostate cancer management continue to be
debated. First, whether tolerance and side
effects of ADT can be diminished by altering
the regimens used, for example, with
intermittent ADT. Second, with the
introduction of newer treatment options,
mainly indicated for metastatic CRPC, there is
a concern among clinical experts that some
physicians may disregard the need for
continued ADT (i.e., ‘backbone ADT’) [62].
The feasibility of intermittent ADT, as an
alternative to continuous androgen deprivation
for improving quality of life while maintaining
disease control, was examined in 2013 in 1535
men with newly diagnosed metastatic
hormone-sensitive prostate cancer, and was
found to be inferior to continuous ADT on
survival outcomes [63]. However, intermittent
ADT may still have a role when patients are not
metastatic, the patient profile fits the choice of
strategy, or because of the strong belief that
toxicity is reduced. This was tested in a
secondary analysis of the trial mentioned
above, with regard to toxicity. The analysis of
intermittent versus continuous ADT suggested
that the 10-year cumulative incidence of
ischaemic and thrombotic events was
significantly higher with intermittent ADT
(33%) versus continuous ADT (24%, P = 0.02).
In conclusion, older men with metastatic
prostate cancer who received intermittent ADT
had no reduction in bone, endocrine or
cognitive events, but ischemic and thrombotic
events were more frequent compared with
continuous ADT [64].
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However, the results from these studies
should be interpreted with caution, and there
is a trend for improved HRQoL with
intermittent versus continuous ADT and
intermittent treatment may have reduced
treatment costs [65]. These uncertainties have
led the EAU to suggest that intermittent ADT
may be an option in patients with metastatic
disease after a standardized induction period
[3].
Another strategy for the management of
asymptomatic disease is to defer ADT until the
development of symptoms. A Cochrane review
of studies from the pre-PSA era suggested that
early ADT in a metastatic population
significantly reduced disease progression and
associated complications [66]. However, the
EAU guidelines highlight the difficulties in
making any recommendations due to the lack
of quality data [3].
On the issue of backbone ADT, the need to
eliminate or suppress as many parts of the
androgen receptor signaling pathway as
possible provides a rationale for continuing
androgen deprivation while inhibiting
androgen biosynthesis with abiraterone [62].
Data suggest that the combination of
abiraterone and ADT provides more sustained
suppression of testosterone than abiraterone
monotherapy [67–69]. Specifically, the use of
abiraterone alone is not able to maintain
decreased levels of testosterone in men who
have not achieved castration, whereas the
addition of abiraterone to backbone ADT
results in sustained suppression of testosterone
to low levels [67–69]. Likewise, the
continuation of ADT when initiating
enzalutamide therapy may help achieve
greater CAB.
The rationale for continuing ADT when
starting chemotherapy in metastatic CRPC
(mCRPC) is that cessation of ADT may cause
renewed testosterone release and stimulation of
the remaining androgen-sensitive elements of
the tumor [62]. Although survival benefits of
lowered testosterone in the setting of metastatic
prostate cancer have not been conclusively
demonstrated, improved overall survival by
13.6 months was shown with the inclusion of
ADT during chemotherapy initiation compared
with ADT alone in men with metastatic prostate
cancer naı¨ve to hormonal therapy from the
CHAARTED (ChemoHormonal therapy versus
Androgen Ablation Randomized Trial for
Extensive Disease in prostate cancer) study
(ClinicalTrials.gov identifier, NCT00309985)
[70]. This study also showed an 8.5 month
increase in median time to biochemical,
symptomatic or radiographic progression with
the addition of chemotherapy. In addition, the
addition of chemotherapy to the first-line
hormonal therapy for high-risk, locally
advanced, metastatic or recurrent prostate
cancer was shown to increase median overall
survival by 10 months in the STAMPEDE trial
(ClinicalTrials.gov identifier, NCT00268476)
[71]. However, the incidence of Grade 3–5 AEs
was considerably higher in the group receiving
chemotherapy than in the group not receiving
chemotherapy [71]. Thus, it seems the
combination of ADT and chemotherapy
should be initiated earlier in the treatment
algorithm for high-risk disease. In patients
who have already initiated ADT, it may be less
clear if potential survival advantages exist by
continuing ADT when chemotherapy is
initiated, but it seems logical to follow expert
guidance that advocates maintaining ADT
when initiating chemotherapy for metastatic
prostate cancer [62].
Irrespective of the above arguments in favor
of maintaining backbone ADT, continuation of
ADT, and maintenance of testosterone levels
\50 ng/dl were stipulated as inclusion criteria
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for entry into all randomized controlled trials of
newer agents (e.g., abiraterone and
enzalutamide) [20, 21, 72, 73], and therefore,
there is no evidence to support stopping ADT
when initiating these other agents. An
important question that requires more data is
whether certain sequences of these treatments
or combinations of ADT and abiraterone and
enzalutamide may benefit some patients.
Several studies have assessed the optimal
sequencing of treatments in different patient
groups [74–77], but firm guidance is not
currently possible.
As well as these issues surrounding ADT, the
use of adjuvant ADT after radical prostatectomy
when nodal involvement is detected continues
to have an important role [3]. Similarly,
adjuvant or neo-adjuvant ADT plus
radiotherapy is established as standard practice
for locally advance prostate cancer, especially
when disease is classified as high risk [3, 78–81].
CONCLUSION
ADT remains the mainstay of treatment for
advanced prostate cancer, with GnRH agonists
predominating as a hormonal therapy of
choice. Triptorelin is a GnRH agonist that is
indicated as the first-line hormonal therapy in
patients with locally advanced non-metastatic
or metastatic disease. The availability of
sustained-release 1-, 3- and 6-month
formulations of triptorelin delivered via IM or
SC routes offers the potential for improved
flexibility and convenience for the patient
with advanced prostate cancer. Moreover,
sustained-release triptorelin treatment has a
proven efficacy and safety profile in clinical
trials, with observations from routine practice
indicating patient satisfaction lending credence
to clinical trial data. It is imperative that the
emergence of new treatment options for
castration-resistant prostate cancer does not
lead physicians to overlook the benefits of
continuing ADT in their patients. However, it
is also clear that optimum treatment
sequencing of ADT, novel hormonal agents,
and chemotherapy needs to be defined and
individualized for men with advanced prostate
cancer.
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